Exelixis, Teva reach settlement on Cabometyx patent dispute
Exelixis has settled a patent dispute over Teva’s attempt to market a generic version of its blockbuster cancer drug Cabometyx, pushing generic competition into the next decade.
The settlement resolves a case brought by Exelixis in Delaware federal court over a patent that expires in 2032 and covers processes to make compounds containing quinolines, a type of organic compound. As part of the deal, Exelixis has agreed to give Teva a license to market its generic version on Jan. 1, 2031, pending FDA approval, Exelixis announced Sunday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.